Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada

References

• Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Toronto: OCCS, 2014
   Google Scholar
• Canadian Cancer Society. Lung Cancer Statistics, 2014. http://www.cancer.ca/~/media/cancer.ca/CW/cancer%20information/cancer%20101/Canadian%20cancer%20statistics/Canadian-Cancer-Statistics-2014-EN.pdf, accessed May 2015
   Google Scholar
• NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 6. National Comprehensive Cancer Network, 2015
   Google Scholar
• Vijayvergia N, Mehra R. Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2014;74:437-46
   PubMed Web of Science ®Google Scholar
• National Cancer Institute, US. SEER Program. Non-small cell cancer of the lung and bronchus (invasive). Table 15.58.
   Google Scholar
• Yang P, Kulig K, Boland J, et al. Worse disease free survival in never smokers with ALK + lung adenocarcinoma. J Thorac Oncol 2012;7:90-7
   PubMed Web of Science ®Google Scholar
• Rodig S, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-23
   PubMed Web of Science ®Google Scholar
• Shaw A, Yeap B, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbour EML4-ALK. J Clin Oncol 2009;27:4247-53
   PubMed Web of Science ®Google Scholar
• Pfizer Canada Inc. Xalkori (crizotinib) Product Monograph. Date of Revision: January 27, 2015
   Google Scholar
• Pan-Canadian Funding Summary: Crizotinib (Xalkori) for advanced Non-Small Cell Lung Cancer. Canadian agency for Drugs and Technologies in Health (CADTH). https://www.cadth.ca/xalkori-advanced-nsclc-resubmission-details. Accessed February 2016
   Google Scholar
• Pan-Canadian Oncology Drug review for crizotinib. https://www.cadth.ca/xalkori-resubmission-first-line-advanced-nsclc-details. Accessed February 2016
   Google Scholar
• Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2012;13:1195-201
   PubMed Web of Science ®Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulf onyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013;56:5675-90
   PubMed Web of Science ®Google Scholar
• Ceritinib product monograph, July 2015
   Google Scholar
• Felip EKD, Kim DW, Mehra R, et al. Efficacy and safety of certinib in patients with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Poster presented at ESMO. 2014;Abstr # 1295P
   Google Scholar
• Ceritinib, European Public Assessment Report. 2015 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003819/WC500187506.pdf. Accessed October 2015
   Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: a single-arm, open-label, multicenter phase 2 study of ceritinib in adult patients (pts) with ALK-Rearranged (ALK+) Non-small Cell Lung Cancer (NSCLC) previously treated with chemotherapy and Crizotinib (CRZ). 2015, Abs # 8059
   Google Scholar
• Sacco JJ, Botten J, Macbeth F, et al. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One 2010;5:e8933
   PubMed Web of Science ®Google Scholar
• Kayaniyil S, Wilson J, Hurry M et al. Economic burden of patients with ALK + mutation non-small cell lung cancer after treatment with crizotinib: a Canadian retrospective observational study. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research. November 2015
   Google Scholar
• Djalalov S, Beca J, Hoch JS, et al. Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer. J Clin Oncol 2014;32:1012-19
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. HTA guidelines for economic evaluation of health technologies: Canada. 3rd edn. 2006
   Google Scholar
• http://digitizer.sourceforge.net.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 2012;12:9
   PubMed Web of Science ®Google Scholar
• Hollander MJ. Costs of end-of life care: findings from the province of Saskatchewan. Healthc Q 2009;12:50-8
   PubMedGoogle Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:2038-45
   PubMed Web of Science ®Google Scholar
• Canadian CPI. http://www.bankofcanada.ca/rates/indicators/capacity-and-inflation-pressures/inflation/historical-data/. Accessed March 2015
   Google Scholar
• Chouaid C, Mitchell PLR, Agulnik J,et al. Health-related quality of life in advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Value Health 2012:A1-A256
   Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
   PubMed Web of Science ®Google Scholar
• Blackhall F, Kim DW, Besse B, et al. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol 2014;9:1625-33
   PubMed Web of Science ®Google Scholar
• Pan-Canadian Oncology Drug review for adcetris. 2013. https://www.cadth.ca/sites/default/files/pcodr/pcodr-adcetrishl-fn-egr.pdf Accessed November 2015
   Google Scholar
• Pan-Canadian Oncology Drug review for bosulif. 2015. https://www.cadth.ca/sites/default/files/pcodr/pcodr_bosutinib_bosulif_cml_fn_egr.pdf. Accessed November 2015
   Google Scholar
• Pan-Canadian Oncology Drug review for ceritinib. https://www.cadth.ca/zykadia-metastatic-non-small-cell-lung-cancer-details. Accessed November 2015
   Google Scholar
• Navaratnam S, Kliewer EV, Butler J, et al. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010;70:110-5
   PubMed Web of Science ®Google Scholar
• Dillon A. Responsiveness, language, and alignment: reflections on some challenges for health technology assessment. Int J Technol Assess Health Care 2015;31:223-225
   Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
   PubMed Web of Science ®Google Scholar
• Mean dose intensity. Novartis Clinical Study Report for ASCEND-1. East Hanover, New Jersey. 2014
   Google Scholar
• Cancer Care Ontario, drug formulary. https://www.cancercare.on.ca/toolbox/drugformulary/. Accessed May 2015.
   Google Scholar
• DeltaPA®, IMSB databases. Accessed May 2015
   Google Scholar
• Ontario Schedule of Benefits for Physician services. 2014 http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html. Accessed May, 2015
   Google Scholar
• http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html. Accessed May 2015
   Google Scholar
• Ontario Case Costing Initiative, 2010/2011 costs. https://hsimi.on.ca/hdbportal/. Accessed May 2015
   Google Scholar